Intra-Cellular Therapies ... (ITCI)
131.81
0.06 (0.05%)
At close: Mar 28, 2025, 3:59 PM
131.83
0.02%
After-hours: Mar 28, 2025, 04:29 PM EDT
Intra-Cellular Therapies Balance Sheet Statement
| Year | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 |
| Cash & Equivalents | 306.95M | 147.77M | 148.62M | 92.36M | 60.05M | 107.64M | 54.95M | 37.79M | 48.64M | 47.16M | 61.33M | 35.15M | 19.15M |
| Short-Term Investments | 694.12M | 350.17M | 443.29M | 319.97M | 597.4M | 116.37M | 292.58M | 426.54M | 335.46M | 428.04M | 68.32M | 2M | 3.5M |
| Long-Term Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Other Long-Term Assets | 44.65M | 45.91M | 86K | 86.08K | 86.08K | 86.08K | 78.83K | 75.77K | 75.77K | 71.88K | 70.94K | 131.56K | 130.75K |
| Receivables | 166.5M | 114.02M | 75.19M | 20.16M | 10.76M | n/a | n/a | n/a | 94.34K | 30.66K | 51.6K | 336.32K | 300.43K |
| Inventory | 26.28M | 11.65M | 23.92M | 7.95M | 7.06M | n/a | n/a | n/a | 1.00 | 1.00 | n/a | 1.00 | 1.00 |
| Other Current Assets | 113.52M | 44.19M | 46.94M | 26.84M | 15.64M | 6.31M | 7.91M | 4.88M | 4.01M | 8.03M | 1.29M | 762.24K | 188.7K |
| Total Current Assets | 1.31B | 667.8M | 737.96M | 467.28M | 690.9M | 230.32M | 355.44M | 469.22M | 388.2M | 483.26M | 130.99M | 38.25M | 19.63M |
| Property-Plant & Equipment | 14.9M | 14.58M | 16.74M | 22.56M | 26.32M | 20.51M | 1.16M | 1.14M | 627.61K | 775.52K | 54.55K | 68.27K | 58.27K |
| Goodwill & Intangibles | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Total Long-Term Assets | 59.55M | 60.5M | 16.82M | 22.64M | 26.41M | 20.86M | 1.77M | 2.27M | 703.38K | 847.4K | 125.5K | 199.83K | 189.02K |
| Total Assets | 1.37B | 728.29M | 754.78M | 489.92M | 717.31M | 251.19M | 357.21M | 471.49M | 388.9M | 484.1M | 131.11M | 38.45M | 19.82M |
| Account Payables | 26.07M | 11.45M | 10.39M | 8.69M | 5.5M | 7.43M | 13.96M | 6.17M | 3.75M | 1.63M | 2.05M | 3.4M | 41.61K |
| Deferred Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 1.67M |
| Short-Term Debt | 4.23M | 3.61M | 9.13M | 6.73M | 5.54M | 3.19M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Other Current Liabilities | 175.4M | 108.48M | 63.71M | 37.93M | 25.81M | 25.61M | 22.34M | 8.04M | 6.78M | 4.63M | 8.5M | 3.44M | 1.13M |
| Total Current Liabilities | 205.7M | 123.55M | 83.24M | 53.36M | 36.85M | 36.22M | 36.3M | 14.21M | 10.53M | 6.26M | 10.56M | 6.83M | 2.84M |
| Long-Term Debt | 12.75M | 13.33M | 15.47M | 18.69B | 23.6M | 19.96M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Other Long-Term Liabilities | n/a | n/a | n/a | -18.67B | n/a | n/a | 3.19M | 2.84M | 2.87M | 1.6M | n/a | n/a | n/a |
| Total Long-Term Liabilities | 12.75M | 13.33M | 15.47M | 18.67M | 23.6M | 19.96M | 3.19M | 2.84M | 2.87M | 1.6M | 2.05M | 3.4M | 1.71M |
| Total Liabilities | 218.45M | 136.87M | 98.71M | 72.03M | 60.45M | 56.18M | 39.49M | 17.05M | 13.4M | 7.86M | 10.56M | 6.83M | 2.84M |
| Total Debt | 16.98M | 16.94M | 20.04M | 25.41M | 29.14M | 23.14M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Common Stock | 11K | 10K | 9K | 8.19K | 8.05K | 5.55K | 5.49K | 5.46K | 4.33K | 4.32K | 2.95K | 2.22K | 1.46K |
| Retained Earnings | -1.69B | -1.62B | -1.48B | -1.22B | -937.1M | -710.1M | -562.38M | -407.25M | -309.48M | -193.05M | -88.26M | -57.56M | -30.7M |
| Comprehensive Income | 191K | 104K | -4.19M | -363.65K | 480.58K | 128.32K | -667.76K | -799.22K | -317.24K | -590.41K | -104.63K | 0.00 | -3.22M |
| Shareholders Equity | 1.15B | 591.42M | 656.07M | 417.89M | 656.86M | 195.01M | 317.71M | 454.44M | 375.5M | 476.24M | 120.55M | 31.62M | 16.98M |
| Total Investments | 694.12M | 350.17M | 443.29M | 319.97M | 597.4M | 116.37M | 292.58M | 426.54M | 335.46M | 428.04M | 68.32M | 2M | 3.5M |